Prosecution Insights
Last updated: October 02, 2026

Examiner: VALLE, ERNESTO

Tech Center 1600 • Art Units: 1623 1625 1654

This examiner grants 66% of resolved cases

Analysis

Ernesto Valle serves in Tech Center 1600 and Art Unit 1623, having completed 38 resolved cases. His allowance rate is 65.8%, which indicates a moderate likelihood of success for applications on his docket. This 65.8% rate provides a clear expectation for practitioners navigating the complexities of this specific art unit. The 38 cases resolved by this examiner offer a consistent look at his typical prosecution outcomes.

The median days to allowance for this examiner is 1260, reflecting a relatively long duration for the patent process. However, the data shows an interview lift of 32.9%, which provides a substantial boost to the probability of success. This positive lift suggests that direct communication can be a very effective tool for resolving outstanding issues. The 1260-day median pendency is an important figure for practitioners to communicate to their clients when setting expectations.

Strategically, the 32.9% interview lift should be considered a primary option for overcoming rejections in Art Unit 1623. While the 65.8% allowance rate shows that success is achievable, the 1260-day median suggests that the process requires steady advocacy. With 38 cases resolved, the examiner's tendencies are becoming clearer, allowing for more informed planning. Applicants should utilize interviews to supplement written responses and potentially improve the odds of a grant.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

65.8%
Allow Rate
+5.8% vs TC avg
86
Total Applications
+32.9%
Interview Lift
1260
Avg Prosecution Days
Based on 38 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%
§101 Eligibility
18.2%
§102 Novelty
40.1%
§103 Obviousness
26.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18706306 PRODRUGS OF AXITINIB Non-Final OA OCULAR THERAPEUTIX, INC.
17789019 TARGETING THE INTRINSIC APOPTOTIC MACHINERY IN GLIOBLASTOMA Final Rejection The Regents of The University Of California
17769454 METHODS OF TREATING OR PREVENTING CACHEXIA Non-Final OA Toray Industries, Inc.
18569581 IMPROVED TREATMENT METHODS FOR CABAZITAXEL Non-Final OA ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED
18455978 Substituted Pyrrolotriazines Non-Final OA Molecure S.A.
17924103 TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) Non-Final OA DURECT CORPORATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month